Channels
drug-pricing-alerts
D
DelamainAPP8:14 AM
🔔 CMS Update — Ozempic added to Round 2 negotiation list
CMS published the expanded drug negotiation list:
• Ozempic (semaglutide) added to Round 2, effective Jan 2027
• Proposed price reduction: 40-55% from current WAC of $30.50/day
Impact:
🔴 National Biopharma Alliance — 4 member companies with semaglutide exposure; est. $180M revenue at risk
🟡 MedPolicy Group — Indirect: cardiovascular indication could widen CMS eligibility scope
⚠️ Conflict Detected — BioVenture Partners and PharmaPolicy Alliance have opposing positions on indication scope
👀 4🚨 2
NS
Niaz Siasi8:18 AM
Thanks for the catch on the conflict. Can you draft talking points for National Biopharma Alliance on why the cardiovascular indication scope should be narrowly defined?
D
DelamainAPP8:21 AM
Done. Drafted 3 talking points for National Biopharma Alliance on narrow indication scope:
1. Clinical precision — CMS should negotiate only for the FDA-approved indication with the highest Medicare utilization, not all indications simultaneously
2. Innovation incentive — Broad scope discourages R&D investment in new indications for existing molecules; 14 pipeline semaglutide programs at risk
3. Precedent risk — Cardiovascular broadening would create template applicable to 8 other drugs in Round 3 negotiations
I've saved the full memo to Client Briefer. Want me to share it with Elizabeth Lee on the health team for review?
✅ 3